VIR

#2049
Vir Biotechnology, Inc. - Common Stock
11.3 1 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
11.31
11.31
Intervallo Annuale
4.81
11.50
Variazione giornaliera
+2.08%
Variazione Mensile
+27.94%
Variazione di 6 mesi
+27.80%
Variazione Annuale
+89.13%
Chiusura Precedente
11.0 8
Open
11.3 1
Minimo
11.3 1
Massimo
11.3 1
Volume
147
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Vir Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Vir Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K

Vir Biotechnology, Inc. current report, Q1 FY2023

Full document

Business Context and Reporting Period

This Form 8-K was filed by Vir Biotechnology, Inc. on February 8, 2023, reporting the entry into a Material Definitive Agreement. The filing details the Second and Third Amendments to the Definitive Collaboration Agreement (DCA) originally entered into with Glaxo Wellcome UK Limited and Beecham S.A. (collectively "GSK") in June 2020.

Key Financial Metrics

The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the structural changes to the collaboration agreement and the resulting royalty obligations.

Material Changes Versus Prior Period

  • Termination of CoV Vaccine Program: Effective March 31, 2022, the CoV Vaccine Program was removed from the DCA. Cost-sharing arrangements and ongoing activities for this program were terminated.
  • Restructuring of CoV Antibody Program: The scope of the collaboration was narrowed to include only sotrovimab, VIR-7832, and certain variants. All other coronavirus antibodies were removed from the DCA.
  • Retention of Rights: Vir retains the sole right to independently develop and commercialize the terminated vaccine products and non-included antibody products.
  • New Royalty Obligations: Vir agreed to pay tiered royalties to GSK on net sales of terminated products:
    • Vaccine products: Low single-digit percentages.
    • Terminated antibody products: Low- to mid-single-digit percentages.

Guidance, Outlook, and Risks

The filing does not contain updated financial guidance or management commentary regarding future performance. The primary risk disclosed relates to the ongoing royalty payments to GSK on future net sales of products developed independently by Vir following the termination of specific programs. The DCA remains in force for the remaining programs (sotrovimab and VIR-7832).

Key Facts for Investor Verification

  • Verify the specific tiered royalty percentages and deduction terms for the terminated vaccine and antibody programs in the full text of the DCA Amendments.
  • Confirm the financial impact of winding down the CoV Vaccine Program cost-sharing arrangements on Vir's future cash burn.
  • Assess the commercial potential of sotrovimab and VIR-7832 as the sole remaining assets under the GSK collaboration.
  • Review subsequent filings for the full text of the DCA Amendments referenced as exhibits.

Notizie